IN2014KN01682A - - Google Patents
Info
- Publication number
- IN2014KN01682A IN2014KN01682A IN1682KON2014A IN2014KN01682A IN 2014KN01682 A IN2014KN01682 A IN 2014KN01682A IN 1682KON2014 A IN1682KON2014 A IN 1682KON2014A IN 2014KN01682 A IN2014KN01682 A IN 2014KN01682A
- Authority
- IN
- India
- Prior art keywords
- human
- receptor antagonist
- mammalian
- expression
- itr
- Prior art date
Links
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 abstract 3
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 abstract 3
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 abstract 3
- 230000014509 gene expression Effects 0.000 abstract 3
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 abstract 3
- 230000001939 inductive effect Effects 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 210000002437 synoviocyte Anatomy 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20120000703 EP2623604B8 (en) | 2012-02-02 | 2012-02-02 | Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis |
| PCT/IB2013/000198 WO2013114199A1 (en) | 2012-02-02 | 2013-01-23 | Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN01682A true IN2014KN01682A (pl) | 2015-10-23 |
Family
ID=47891791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1682KON2014 IN2014KN01682A (pl) | 2012-02-02 | 2013-01-23 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10301647B2 (pl) |
| EP (1) | EP2623604B8 (pl) |
| JP (2) | JP6340320B2 (pl) |
| CN (1) | CN104245941B (pl) |
| AU (1) | AU2013213873B2 (pl) |
| CA (1) | CA2861408C (pl) |
| DK (1) | DK2623604T3 (pl) |
| EA (1) | EA033004B1 (pl) |
| ES (1) | ES2534782T3 (pl) |
| IN (1) | IN2014KN01682A (pl) |
| PL (1) | PL2623604T3 (pl) |
| WO (1) | WO2013114199A1 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2802878T3 (es) | 2013-01-25 | 2021-01-21 | Baylor College Medicine | Un sistema de administración y expresión de terapia génica adenoviral dependiente de linfocitos T colaboradores |
| GB201410314D0 (en) * | 2014-06-10 | 2014-07-23 | Advanced Risc Mach Ltd | Display controller |
| JP7095993B2 (ja) * | 2015-03-02 | 2022-07-05 | シンロジック オペレーティング カンパニー インコーポレイテッド | 消化管炎症低下および／または消化管粘膜バリア強化の利益を享受する疾患処置のために操作された細菌 |
| RU2771490C2 (ru) | 2016-01-13 | 2022-05-05 | Мериал, Инк. | Рекомбинантные aav векторы, экспрессирующие остеопротективные гены, включая has2 и лубрицин, пригодные при лечении остеоартрита и сходных заболеваний суставов у млекопитающих |
| JP7165410B2 (ja) * | 2016-08-19 | 2022-11-04 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド | 組換え自己相補的アデノ随伴ウイルスを使用して疾患を治療するための方法及び組成物 |
| WO2018071295A1 (en) | 2016-10-10 | 2018-04-19 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for inducible production of anti-inflammatory cytokines |
| KR20190088561A (ko) * | 2016-12-07 | 2019-07-26 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 인터류킨-1 수용체 길항제(IL-1RA) cDNA |
| CA3060573A1 (en) | 2017-04-21 | 2018-10-25 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
| WO2021055860A1 (en) * | 2019-09-18 | 2021-03-25 | Flexion Therapeutics, Inc. | Effective dosages of an adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis in humans, and compositions comprising the same |
| WO2021097325A1 (en) * | 2019-11-14 | 2021-05-20 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| US20240230658A1 (en) * | 2021-05-06 | 2024-07-11 | Rigaku Corporation | X-ray contrast medium and x-ray image acquisition method |
| EP4392138A4 (en) * | 2021-08-24 | 2025-07-23 | Pacira Therapeutics Inc | IL-1RA GENE THERAPY FOR INTERVERTEBRAL DISC DEGENERATION |
| AU2024228620A1 (en) | 2023-03-02 | 2025-08-28 | Pacira Germany Gmbh | Compositions and methods for improved adenoviral- based gene therapy utilizing corticosteroid treatment |
| WO2024213660A1 (en) * | 2023-04-13 | 2024-10-17 | Meiragtx Uk Ii Limited | Inflammation-inducible promoters |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747072A (en) | 1993-07-30 | 1998-05-05 | University Of Michigan | Adenoviral-mediated gene transfer to synovial cells in vivo |
| US20030091536A1 (en) | 1999-09-07 | 2003-05-15 | Colorado State University Research Foundation | In vivo treatment of joint disease using interleukin-1 |
| FR2806418B1 (fr) * | 2000-03-14 | 2004-07-16 | Aventis Pharma Sa | Promoteurs hybrides inductibles par l'inflammation, vecteurs les contenant et utilisations |
| AU2002311777A1 (en) | 2001-04-17 | 2002-10-28 | Genetix Pharmaceuticals, Inc. | Method of treating arthritis using lentiviral vectors in gene therapy |
| HUE029021T2 (en) * | 2005-06-21 | 2017-02-28 | Xoma (Us) Llc | IL-1beta-binding antibodies and fragments thereof |
| US8298533B2 (en) * | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| CN102460162A (zh) * | 2009-05-01 | 2012-05-16 | 俄勒冈健康科学大学 | 体内扩增人肝细胞的方法 |
| SG10201500180RA (en) * | 2009-05-29 | 2015-03-30 | Xoma Us Llc | CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF |
-
2012
- 2012-02-02 DK DK12000703.4T patent/DK2623604T3/da active
- 2012-02-02 EP EP20120000703 patent/EP2623604B8/en active Active
- 2012-02-02 ES ES12000703.4T patent/ES2534782T3/es active Active
- 2012-02-02 PL PL12000703T patent/PL2623604T3/pl unknown
-
2013
- 2013-01-23 US US14/375,351 patent/US10301647B2/en active Active
- 2013-01-23 CA CA2861408A patent/CA2861408C/en active Active
- 2013-01-23 AU AU2013213873A patent/AU2013213873B2/en active Active
- 2013-01-23 EA EA201491457A patent/EA033004B1/ru unknown
- 2013-01-23 JP JP2014555328A patent/JP6340320B2/ja active Active
- 2013-01-23 IN IN1682KON2014 patent/IN2014KN01682A/en unknown
- 2013-01-23 CN CN201380007814.1A patent/CN104245941B/zh active Active
- 2013-01-23 WO PCT/IB2013/000198 patent/WO2013114199A1/en not_active Ceased
-
2018
- 2018-02-01 JP JP2018016342A patent/JP2018075035A/ja active Pending
-
2019
- 2019-04-30 US US16/398,691 patent/US20190376080A1/en not_active Abandoned
-
2021
- 2021-10-08 US US17/497,045 patent/US20220073948A1/en not_active Abandoned
-
2022
- 2022-06-30 US US17/855,322 patent/US20220348963A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10301647B2 (en) | 2019-05-28 |
| CN104245941A (zh) | 2014-12-24 |
| EA201491457A1 (ru) | 2014-11-28 |
| JP2015506695A (ja) | 2015-03-05 |
| ES2534782T3 (es) | 2015-04-28 |
| US20190376080A1 (en) | 2019-12-12 |
| CA2861408A1 (en) | 2013-08-08 |
| EP2623604A1 (en) | 2013-08-07 |
| JP2018075035A (ja) | 2018-05-17 |
| WO2013114199A1 (en) | 2013-08-08 |
| US20220348963A1 (en) | 2022-11-03 |
| EP2623604B1 (en) | 2015-02-25 |
| EA033004B1 (ru) | 2019-08-30 |
| US20220073948A1 (en) | 2022-03-10 |
| DK2623604T3 (da) | 2015-06-01 |
| JP6340320B2 (ja) | 2018-06-06 |
| CN104245941B (zh) | 2016-12-07 |
| CA2861408C (en) | 2021-10-26 |
| AU2013213873A1 (en) | 2014-09-25 |
| PL2623604T3 (pl) | 2015-07-31 |
| US20150031083A1 (en) | 2015-01-29 |
| EP2623604B8 (en) | 2015-04-22 |
| AU2013213873B2 (en) | 2018-06-21 |
| WO2013114199A8 (en) | 2014-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014KN01682A (pl) | ||
| Zhang et al. | MiR-637 maintains the balance between adipocytes and osteoblasts by directly targeting Osterix | |
| Fayyad-Kazan et al. | Downregulation of microRNA-24 and-181 parallels the upregulation of IFN-γ secreted by activated human CD4 lymphocytes | |
| Chen et al. | Mesenchymal stem cells modified with heme oxygenase-1 have enhanced paracrine function and attenuate lipopolysaccharide-induced inflammatory and oxidative damage in pulmonary microvascular endothelial cells | |
| PH12020550156A1 (en) | 4-1bb binding molecules | |
| EP4706680A3 (en) | A method for high level and stable gene transfer in lymphocytes | |
| NZ603813A (en) | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases | |
| PH12014500348A1 (en) | Genes and proteins for alkanoyl-coa synthesis | |
| WO2022038264A1 (en) | Modified lymphocytes | |
| MX354516B (es) | Vectores que codifican el factor de viabilidad de conos derivado de bastones. | |
| IN2014DN06789A (pl) | ||
| MX359953B (es) | Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada. | |
| MX2013003681A (es) | Ácidos nucleicos manipulados y métodos de uso de los mismos. | |
| EA201692359A1 (ru) | Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса | |
| NZ628126A (en) | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases | |
| MX2021011039A (es) | Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii. | |
| NZ616989A (en) | Therapeutic nuclease compositions and methods | |
| IN2014KN02823A (pl) | ||
| MX354016B (es) | Sistemas y metodos de suministro de agentes bioactivos mediante el uso de secuencias transportadoras derivadas de toxinas. | |
| BRPI0607119A2 (pt) | construção de ácido nucleico, população de construções de ácido nucleico, seqüência promotora quimérica isolada purificada, partìculas revestidas, receptáculo de dosagem para um dispositivo de liberação mediada por partìcula, dispositivo de liberação mediada por partìcula, composição farmacêutica, composição de vacina, e, método in vitro de obter a expressão em células de mamìfero de um polipeptìdeo da influenza de interesse | |
| Boura et al. | Evaluation of gene delivery strategies to efficiently overexpress functional HLA-G on human bone marrow stromal cells | |
| MX2013010392A (es) | Proteinas de fusion npp1. | |
| EA033437B1 (ru) | Fc-гамма-рецептор iib и его применение для лечения или предупреждения воспалительных и/или аутоиммунных заболеваний | |
| WO2013096958A8 (en) | Compositions and methods for the delivery of biologically active rnas | |
| Han et al. | Delivery of episomal vectors into primary cells by means of commercial transfection reagents |